Is Armour Thyroid Safe in the First Trimester? A Women's Health Guide

What Armour Thyroid Actually Is (and Why Pregnancy Changes Everything)

Armour Thyroid is a brand of natural desiccated thyroid extracted from porcine (pig) thyroid glands. Each grain contains both levothyroxine (T4) and liothyronine (T3) in a fixed 4:1 ratio by weight. That dual-hormone combination is what makes NDT different from synthetic levothyroxine alone, and it is exactly that difference that raises questions the moment a positive pregnancy test appears.

Pregnancy is not a stable physiological state for thyroid physiology. From roughly week 4 to week 6, thyroid hormone demand rises sharply because the fetus cannot produce its own thyroid hormone until about gestational week 10-12. Before the fetal thyroid becomes functional, your thyroid hormone is the only supply your baby's developing brain has. Even a brief dip in free T4 during this window is associated with measurable effects on fetal neurodevelopment.

Why the T3 Component Matters More Than You Might Think

T3 is biologically active and three to four times more potent than T4. In a non-pregnant adult, the body converts T4 to T3 in peripheral tissues, keeping serum T3 relatively stable. Pregnancy complicates this. The placenta expresses type 3 deiodinase, an enzyme that actively degrades T3 to reverse T3 (rT3), limiting fetal T3 exposure. So while that placental barrier offers some protection against maternal T3 excess, it also means the T3 in Armour Thyroid does not contribute meaningfully to fetal thyroid supply. The T4 component does, because the fetus converts maternal T4 to T3 locally in fetal tissues.

The practical consequence: NDT gives you a fixed, non-adjustable T3 dose in every tablet. If your dose is increased to meet rising pregnancy T4 demands, your T3 intake rises proportionally. That T3 spike can suppress your own pituitary TSH and make standard TSH-based monitoring harder to interpret accurately.

The Fixed T3:T4 Ratio Problem in Dose Escalation

During pregnancy, most women with hypothyroidism need to increase their thyroid hormone dose by approximately 30-50% above their pre-pregnancy requirement, sometimes even before a missed period. With levothyroxine, a provider can fine-tune the T4 dose independently. With NDT, every dose increase delivers more T3 alongside more T4. There is no way to separate the two components without switching formulations.

What the Guidelines Say

The 2017 American Thyroid Association (ATA) guidelines on thyroid disease in pregnancy state that levothyroxine is the recommended thyroid hormone replacement in pregnancy and that NDT preparations are not recommended for use during pregnancy. The guideline language is direct: the variable hormone content and the fixed T3:T4 ratio make dosing adjustments more complicated when fetal wellbeing depends on precise maternal free T4 levels.

ACOG reinforces this position. Their guidance on thyroid disease in pregnancy endorses levothyroxine as the standard of care and does not list NDT as an acceptable alternative for pregnant patients.

What "Not Recommended" Actually Means in Clinical Practice

"Not recommended" is not the same as "proven harmful." There is a critical distinction worth understanding. No large randomized controlled trial has compared NDT to levothyroxine specifically in pregnant women, partly because conducting such a trial in the first trimester would raise serious ethical concerns. The guidance against NDT in pregnancy is based on:

• Pharmacokinetic reasoning (the T3:T4 ratio mismatch with pregnancy physiology)
• The absence of safety data specifically in pregnant women
• The established efficacy and predictability of levothyroxine

The honest assessment: the guidelines reflect expert consensus built on physiological principles and observational data, not a head-to-head pregnancy trial. Women have been under-represented in thyroid pharmacology trials for decades, and that evidence gap is real. What we can say is that levothyroxine has a well-characterized safety profile across all three trimesters, and NDT does not.

Armour Thyroid in the First Trimester: The Specific Risks

The first trimester carries the highest stakes. Fetal brain development, including cortical neuron migration and myelination initiation, depends on maternal thyroid hormone from conception through roughly week 12. Maternal hypothyroidism in the first trimester is associated with lower childhood IQ, impaired motor development, and increased miscarriage risk.

Undertreated Hypothyroidism Is the Bigger Threat

The data on untreated or undertreated maternal hypothyroidism is sobering. The landmark Haddow et al. Study found that children born to women with undiagnosed or untreated hypothyroidism in pregnancy scored an average of 7 IQ points lower than controls at age 7-9. That study was conducted before widespread thyroid screening in pregnancy and remains a cornerstone of the case for treating maternal hypothyroidism aggressively.

The risk of undertreatment is relevant to the NDT discussion because women taking NDT who discover they are pregnant may be tempted to continue their current dose rather than switch formulations mid-first-trimester. Any decision that delays optimizing free T4 levels carries its own risks.

TSH Suppression and Monitoring Complications

Women on NDT often run lower TSH levels than women on levothyroxine at equivalent thyroid replacement doses. In pregnancy, the ATA recommends maintaining TSH below 2.5 mIU/L in the first trimester, and some clinicians aim for 1.0-1.5 mIU/L. The T3 component of NDT can suppress TSH independently of T4 status, making it genuinely difficult to know whether a low TSH reflects adequate T4 replacement or simply T3 excess. Relying on TSH alone to guide NDT dosing in pregnancy is unreliable.

Potency Variability Between Lots

NDT is a biological product, not a chemically synthesized drug. Hormone content can vary modestly between manufacturing lots. The FDA has noted variability in NDT potency, and while this variability is typically small, it becomes clinically relevant during a period when even a 10-15% change in T4 availability can affect fetal development.

Pregnancy and Lactation Safety: What the Data Actually Shows

The following framework organizes what is directly studied versus what is extrapolated from physiological reasoning, because conflating the two is a disservice to women making real decisions.

Pregnancy: Human Data

There are no published randomized controlled trials of NDT versus levothyroxine in pregnant women. The available human evidence consists of:

• Case reports and small case series of women who continued NDT through pregnancy without documented fetal harm
• Pharmacokinetic data showing placental T3 degradation by type 3 deiodinase
• Observational cohort data on hypothyroid women in pregnancy (almost all treated with levothyroxine, not NDT)

The FDA prescribing information for Armour Thyroid notes that thyroid hormones do not readily cross the placental barrier and that adequate maternal thyroid hormone levels are essential for normal fetal development. The label does not carry a formal contraindication in pregnancy, but it also does not provide reassuring human efficacy or safety data specific to NDT in pregnancy.

First Trimester Specifically

No human study has reported outcomes specifically from first-trimester NDT use. What is extrapolated from physiology:

• T4 from NDT crosses the placenta and can support fetal thyroid hormone needs
• T3 from NDT is largely degraded by placental deiodinase and does not contribute substantially to fetal T3 supply
• The T3 component may suppress maternal TSH, complicating standard monitoring

Lactation and Breastfeeding

Both T4 and T3 transfer into human breast milk in small amounts. LactMed reports that thyroid hormones are present in breast milk at low concentrations and are considered compatible with breastfeeding at replacement doses. There is no evidence that maternal thyroid hormone replacement at standard doses harms a nursing infant.

The caveat with NDT specifically: T3 transfer into milk is slightly higher per microgram than T4 transfer, and T3 is more bioavailable orally. At replacement doses, this is not considered clinically significant. If a provider prescribes NDT postpartum during breastfeeding, standard replacement dosing is generally considered low-risk. Supraphysiologic doses would require more caution.

Practical guidance: if you are breastfeeding and taking NDT, have your own thyroid function monitored at least every 6-8 weeks postpartum, because thyroid status can shift significantly in the weeks after delivery, particularly in women with Hashimoto thyroiditis who may experience postpartum thyroiditis flares.

Contraception Note

NDT is not a teratogen in the classical sense, and no specific contraception requirement is attached to it the way there is for drugs like valproate or isotretinoin. The concern in pregnancy is inadequate or imprecise dosing, not embryotoxicity from the drug itself. Women of reproductive age who want to conceive should discuss thyroid optimization before conception, not after a positive test.

Who This Is Right For and Who Should Switch

Women Who Are Already Pregnant

If you are pregnant and currently taking Armour Thyroid, do not stop your medication. Stopping thyroid hormone replacement causes rapid hypothyroidism, and that is far more dangerous to your pregnancy than continuing NDT while arranging an urgent appointment. Contact your prescriber the same day you see a positive test.

Most endocrinologists and maternal-fetal medicine specialists will recommend switching to levothyroxine at this point, partly for guideline compliance and partly for more precise dose titration. The transition is straightforward: a common conversion uses roughly 1 grain of NDT (60-65 mg) as approximately equivalent to 100 mcg of levothyroxine, though individual conversion varies and free T4 levels should guide the final dose.

Women Trying to Conceive

If you are actively trying to conceive and currently taking Armour Thyroid, this is the ideal window to have a preconception thyroid conversation with your provider. Optimizing your thyroid status before pregnancy is easier and safer than adjusting mid-first-trimester. A preconception TSH below 2.5 mIU/L is generally the target. If you and your provider decide to switch to levothyroxine before conception, allow 6-8 weeks to stabilize your levels before actively trying to conceive.

Women with PCOS and Hashimoto Thyroiditis

PCOS and Hashimoto thyroiditis co-occur at higher rates than chance. Women with PCOS have a significantly higher prevalence of thyroid autoimmunity compared to the general population. If you have both conditions and are trying to conceive, thyroid optimization is especially relevant: subclinical hypothyroidism is associated with lower IVF success rates and higher miscarriage rates in this group. NDT use in this scenario adds complexity to dose management without clear benefit over levothyroxine.

Women Who Prefer NDT and Are Not Planning Pregnancy

Outside of pregnancy, the evidence comparing NDT to levothyroxine is more nuanced. A 2019 randomized crossover trial by Idrees et al. Published in The Journal of Clinical Endocrinology and Metabolism found that 49% of participants preferred NDT over levothyroxine, reporting better mood and quality-of-life scores. For women who are not pregnant and not trying to conceive, NDT remains a reasonable option when managed carefully, with the understanding that guidelines still favor levothyroxine as first-line.

How Thyroid Physiology Changes Across Reproductive Life Stages

Reproductive Years (Pre-Conception)

During normal menstrual cycles, thyroid hormone levels remain relatively stable, though free T4 may dip slightly in the luteal phase. Women with Hashimoto thyroiditis may notice that symptoms fluctuate with their cycle. If your thyroid function is well-controlled on NDT and you are not planning pregnancy, routine monitoring every 6-12 months is standard.

Trying to Conceive

TSH should be checked before attempting conception. The ATA recommends a preconception TSH below 2.5 mIU/L for women with known hypothyroidism. If you are on NDT and your TSH is running at or above this threshold, dose adjustment is needed before you start trying.

First Trimester

As described throughout this article, this is the most sensitive window. Thyroid hormone demand rises quickly. Many providers recommend increasing levothyroxine dose by two additional doses per week (roughly 29% increase) as soon as pregnancy is confirmed and then checking TSH and free T4 within 4 weeks. This protocol does not directly translate to NDT because of the T3:T4 ratio issue.

Second and Third Trimester

Thyroid hormone requirements typically stabilize or continue to rise modestly after the first trimester. Monitoring every 4-6 weeks through the second trimester and every 6-8 weeks in the third trimester is standard. After delivery, most women can return to their pre-pregnancy dose, though those with Hashimoto thyroiditis should watch for postpartum thyroiditis, which can cause transient hyperthyroidism followed by hypothyroidism in the months after delivery.

Perimenopause and Post-Menopause

Thyroid disease prevalence rises with age, and women are five to eight times more likely than men to develop hypothyroidism across their lifetime. In perimenopause, symptoms of thyroid dysfunction (fatigue, weight changes, mood shifts, sleep disruption) overlap significantly with menopause symptoms, making accurate diagnosis important. If you are perimenopausal and taking NDT, be aware that hormone therapy (estrogen specifically) increases thyroid-binding globulin, which may increase your total T4 requirement and require a dose adjustment.

Switching From Armour Thyroid to Levothyroxine in Pregnancy: Practical Steps

Switching mid-first-trimester feels daunting, but the process is medically straightforward when done with close monitoring.

1. Get a baseline free T4 and TSH drawn immediately on confirmation of pregnancy.
2. Convert your current NDT dose to an estimated levothyroxine equivalent (approximately 100 mcg levothyroxine per 1 grain of NDT, adjusted based on your labs).
3. Recheck free T4 and TSH in 4 weeks. Do not wait for symptoms.
4. Target free T4 in the upper half of the normal reference range and TSH below 2.5 mIU/L in the first trimester.
5. Tell your obstetric provider about the switch so it is documented in your pregnancy record.

Some women ask whether they can stay on NDT through pregnancy with very close monitoring. The honest answer: a small number of women do this, particularly when they have had poor quality-of-life on levothyroxine previously, and there are no case reports of NDT-specific fetal harm at replacement doses. What there is, is the absence of safety data and a guideline recommendation against it. That combination makes most clinicians and most informed patients elect to switch.

What to Tell Your Provider

If your provider is unfamiliar with NDT or dismisses your questions about it, these are reasonable points to raise:

• Ask specifically about free T4 monitoring, not just TSH, because TSH can be artificially suppressed by the T3 component.
• Ask how your provider will handle dose adjustments if your free T4 drops mid-trimester.
• Ask about timing for the postpartum return to NDT if that is your preference outside of pregnancy.

The goal is not to argue for NDT in pregnancy. The goal is to have a precise, individualized plan that keeps your free T4 adequate through all three trimesters and protects fetal neurodevelopment. For the vast majority of women, levothyroxine is the cleaner tool for that job during pregnancy. After delivery, revisiting NDT is a conversation worth having if it worked better for you before.